The phosphatidylinositol-3-kinase (PI3K) pathway plays a crucial role in cell growth and survival and is activated in various cancers. Multiple components of the pathway are frequently targeted by ...

A newly published review in Genes & Diseases explores the oncogenic activation of PIK3CA in cancer and highlights emerging targeted therapies designed to improve treatment efficacy while reducing side ...

The current PI3K 3C inhibitors in use in advanced breast cancer are alpelisib and inavolisib. Capivasertib is an AKT inhibitor, which is also used in PI3K 3C mutated breast cancer. So these are ...

Despite these differences, the authors found that chemotaxis and electrotaxis share a dependence on similar intracellular signaling molecules, most notably the phosphoinositide 3-kinase (PI3K ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. There are several clinical trials ...

PI3K inhibitors. Alpelisib (Piqray) and inavolisib (Itovebi) block a type of PI3K protein in cancer cells and can be used to treat certain types of breast cancer with a PIK3CA gene mutation.

Researchers from SRM Institute of Science and Technology, led by Dr. KN Aruljothi, have published a study in ExRNA ...

Phagocytosis is a fundamental mechanism used by the body to resist pathogens and restore physiological homeostasis. Herein, to identify small molecules with anti-inflammatory properties via ...

Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an analysis of CELC stock now.

Torqur AG, an innovative clinical-stage biotechnology company dedicated to advancing treatments for oncology and dermatology, ...

The laboratory is studying small molecules that selectively inhibit the components of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. These compounds are being used as reagents to define the role of these ...

Plectin drives hepatocellular carcinoma progression and metastasis through cytoskeletal reorganization and oncogenic signaling, making it a promising therapeutic target for overcoming therapy ...